Wolters Kluwer Health is expanding its Sentri7 clinical surveillance suite to include the Sentri7 drug diversion solution, formerly Flowlytics from Invistics. Sentri7 Drug Diversion employs artificial intelligence (AI) for advanced drug diversion surveillance. The solution helps ensure proactive monitoring and detection of drug diversion, safeguarding against potential risks. By integrating AI-powered analytics, the system aims to enhance patient safety, compliance, and operational efficiency. Other system functionalities include a clinical surveillance suite offering solutions to improve sepsis detection and management; optimize medication use, opioid management, and antimicrobial stewardship; and streamline infection prevention.